OBJECTIVE: Cytoreductive surgery and platinum-based systemic therapy constitute the standard treatment of patients with advanced ovarian cancer. The aim of the present study was to evaluate whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome. METHODS: Data of 191 patients with advanced serous (FIGO III-IV) ovarian cancer from the prospective multicenter study OVCAD (OVarian CAncer Diagnosis) were analyzed. All patients underwent primary surgery followed by platinum-based chemotherapy. RESULTS: The 25%, 50%, and 75% quartiles of intervals from surgery to start of chemotherapy were 22, 28, and 38 days, respectively (range, 4-158 days). Preoperative performance status (P<0.001), extent of surgery (P<0.001), and perioperative complications (P<0.001) correlated with intervals from surgery to initiation of chemotherapy. Timing of cytotoxic treatment [≤ 28 days versus >28 days; hazard ratio (HR) 1.73 (95% confidence interval 1.08-2.78), P=0.022], residual disease [HR 2.95 (95% confidence interval 1.87-4.67), P<0.001], and FIGO stage [HR 2.26 (95% confidence interval 1.41-3.64), P=0.001] were significant prognostic factors for overall survival in multivariate analysis. While the interval from surgery to start of chemotherapy did not possess prognostic significance in patients without postoperative residual disease (n=121), it significantly correlated with overall survival in patients with postoperative residual disease [n=70, HR 2.24 (95% confidence interval 1.08-4.66), P=0.031]. CONCLUSION: Our findings suggest that delayed initiation of chemotherapy might compromise overall survival in patients with advanced serous ovarian cancer, especially when suboptimally debulked.
OBJECTIVE: Cytoreductive surgery and platinum-based systemic therapy constitute the standard treatment of patients with advanced ovarian cancer. The aim of the present study was to evaluate whether the time interval from surgery to start of chemotherapy has an impact on clinical outcome. METHODS: Data of 191 patients with advanced serous (FIGO III-IV) ovarian cancer from the prospective multicenter study OVCAD (OVarian CAncer Diagnosis) were analyzed. All patients underwent primary surgery followed by platinum-based chemotherapy. RESULTS: The 25%, 50%, and 75% quartiles of intervals from surgery to start of chemotherapy were 22, 28, and 38 days, respectively (range, 4-158 days). Preoperative performance status (P<0.001), extent of surgery (P<0.001), and perioperative complications (P<0.001) correlated with intervals from surgery to initiation of chemotherapy. Timing of cytotoxic treatment [≤ 28 days versus >28 days; hazard ratio (HR) 1.73 (95% confidence interval 1.08-2.78), P=0.022], residual disease [HR 2.95 (95% confidence interval 1.87-4.67), P<0.001], and FIGO stage [HR 2.26 (95% confidence interval 1.41-3.64), P=0.001] were significant prognostic factors for overall survival in multivariate analysis. While the interval from surgery to start of chemotherapy did not possess prognostic significance in patients without postoperative residual disease (n=121), it significantly correlated with overall survival in patients with postoperative residual disease [n=70, HR 2.24 (95% confidence interval 1.08-4.66), P=0.031]. CONCLUSION: Our findings suggest that delayed initiation of chemotherapy might compromise overall survival in patients with advanced serous ovarian cancer, especially when suboptimally debulked.
Authors: Anna Ivanova; Anneli Loo; Shelley Tworoger; Christopher P Crum; Isabel Fan; John R McLaughlin; Barry Rosen; Harvey Risch; Steven A Narod; Joanne Kotsopoulos Journal: Cancer Causes Control Date: 2015-03-13 Impact factor: 2.506
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26
Authors: Paul D P Pharoah; Honglin Song; Ed Dicks; Maria P Intermaggio; Patricia Harrington; Caroline Baynes; Kathryn Alsop; Natalia Bogdanova; Mine S Cicek; Julie M Cunningham; Brooke L Fridley; Aleksandra Gentry-Maharaj; Peter Hillemanns; Shashi Lele; Jenny Lester; Valerie McGuire; Kirsten B Moysich; Samantha Poblete; Weiva Sieh; Lara Sucheston-Campbell; Martin Widschwendter; Alice S Whittemore; Thilo Dörk; Usha Menon; Kunle Odunsi; Ellen L Goode; Beth Y Karlan; David D Bowtell; Simon A Gayther; Susan J Ramus Journal: J Natl Cancer Inst Date: 2016-01-27 Impact factor: 13.506
Authors: Shengqing Gu; Stephanie Lheureux; Azin Sayad; Paulina Cybulska; Liat Hogen; Iryna Vyarvelska; Dongsheng Tu; Wendy R Parulekar; Matthew Nankivell; Sean Kehoe; Dennis S Chi; Douglas A Levine; Marcus Q Bernardini; Barry Rosen; Amit Oza; Myles Brown; Benjamin G Neel Journal: Proc Natl Acad Sci U S A Date: 2021-06-22 Impact factor: 11.205